Skip to main content
Delfa

← Trials/Trial dossier/NCT00505167

CompletedPhase 4

Memantine Versus Donepezil in Early Stages of Alzheimer's Disease

Memantine Versus Donepezil in Mild to Moderate Alzheimer's Disease. A Randomized Trial With Magnetic Resonance Spectroscopy.

Assets

Donepezil / Memantine

Listed sites

3

Recruiting sites

-

Enrollment

64

actual

Study population

Alzheimer’s disease

Key I/E criterion

•Alzheimer's disease

Primary endpoint

•Changes in the Levels of the metabolite N-acetyl-aspartate in several areas

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study ID0910-0459
NCT IDNCT00505167

Timeline

Milestones

Study start2007-07 (month precision)
Study first posted2007-07-23estimated
Primary completion2008-07actual (month precision)
Study completion2008-12actual (month precision)
Last update posted2008-12-29estimated

Assets

Drug assets

DonepezilMemantine

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Clinical criteria of probable Alzheimer's disease in the stages mild-to-moderate with a Mini-Mental score higher than 15 points

Exclusion criteria

•Previous treatment with anticholinesterase drugs or memantine.
•Advanced stages of the disease
•Lack of a reliable caregiver.
•Dementias other than Alzheimer's disease

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other (unclassified)

2 endpoints
Primary/protocol endpoint/low confidence

Changes in the Levels of the metabolite N-acetyl-aspartate in several areas of the brain.

Time frame:6 months

descriptive

Secondary/protocol endpoint/low confidence

Changes in the clinical scales observed after treatment

Time frame:6 months

descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 21, 2026
Endpoint classificationDelfa ADRD endpoint taxonomy
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.